Avidity Biosciences, Inc.

Avidity Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody oligonucleotide conjugates (AOCs), an innovative class of RNA therapeutics. Its proprietary AOC platform integrates the targeting precision of monoclonal antibodies with the gene-modulating capabilities of oligonucleotides to deliver treatments directly to muscle cells, addressing previously challenging diseases in neuromuscular and cardiac areas. The company's pipeline features multiple programs in advanced clinical stages, including delpacibart etedesiran in Phase 3 for myotonic dystrophy type 1, delpacibart braxlosiran in Phase 1/2 for facioscapulohumeral muscular dystrophy, and delpacibart zotadirsen in Phase 2 for Duchenne muscular dystrophy. Avidity Biosciences, Inc. also advances precision cardiology candidates like AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Incorporated in 2012 and headquartered in San Diego, California, the company plays a key role in advancing targeted RNA therapies for rare genetic disorders within the biotechnology sector.